ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 282,69
0,14%
Dow Jones
43 297,03
0,91%
DAX
19 848,77
-0,34%
Brent Oil
73,305
0,03%
Bitcoin
98 138,31
-1,17%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Omega Therapeutics Inc (OMGA) Cours

Omega Therapeutics Inc

Omega Therapeutics Inc (OMGA)

Omega Pacific Resources Inc
0,8322
0,0212
(2,61%)
Fermé 26 Décembre 10:00PM
Retardé de 15 minutes
0,8322
0,00
(0,00%)
Après les heures de négociation: 9:59PM
Retardé de 15 minutes

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
0,8322
Prix Achat
0,8322
Prix Vente
0,88
Volume échangé
130 456
0,80 Fourchette du Jour 0,8738
0,75 Plage de 52 semaines 6,30
Cap du marché
46,076M
Clôture Veille
0,811
Ouverture
0,80
Dernière Transaction
35
@
0.88
Dernière heure de transaction
Volume financier
US$ 109 070
VWAP
0,836066
Volume moyen (3 m)
328 850
Actions en circulation
55 366 213
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-0,47
Bénéfice par action (BPA)
-1,76
Chiffre d'affairess
3,09M
Bénéfice net
-97,43M

À propos de Omega Therapeutics Inc

Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to trans... Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to transform the practice of human medicine through highly selective and direct control of the human genome to treat and cure disease. Show more

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Site Web
www.omegatherapeutics.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Omega Therapeutics Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker OMGA. Le dernier cours de clôture d'Omega Therapeutics était de US$0,81. Au cours de la dernière année, les actions de Omega Therapeutics ont été négociées dans une fourchette de prix de US$ 0,75 à US$ 6,30.

Omega Therapeutics compte actuellement 55 366 213 actions en circulation. La capitalisation boursière d'Omega Therapeutics est de US$44,90 million. Omega Therapeutics a un ratio cours/bénéfice (ratio PE) de -0.47.

OMGA Dernières nouvelles

Plus de nouvelles

Form 8-K - Current report

06 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

05 Décembre 2024
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

05 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

27 Novembre 2024
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

27 Novembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

16 Novembre 2024
Edgar (US Regulatory)

Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results

Established clinical proof-of-mechanism and validation of epigenomic controllers as potential new class of medicines from completed Phase 1 MYCHELANGELO™ I trial for c-MYC in HCC; Company...

14 Novembre 2024
GlobeNewswire Inc.

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence PR Newswire CAMBRIDGE, Masss. and LONDON, Oct...

23 Octobre 2024
PR Newswire (US)

Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of...

15 Octobre 2024
GlobeNewswire Inc.

Form 8-K - Current report

04 Octobre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.0178-2.094117647060.850.91950.7821847890.83067636CS
4-0.0278-3.232558139530.861.040.782475700.90097188CS
12-0.4178-33.4241.251.690.753288501.0467056CS
26-1.5178-64.58723404262.352.6250.752875531.39215959CS
52-1.6578-66.5783132532.496.30.757885243.90779987CS
156-14.3878-94.532194480915.2215.220.753517974.24626896CS
260-21.2678-96.234389140322.131.410.753226084.85796256CS

OMGA - Frequently Asked Questions (FAQ)

What is the current Omega Therapeutics share price?
The current share price of Omega Therapeutics is US$ 0,8322
How many Omega Therapeutics shares are in issue?
Omega Therapeutics has 55 366 213 shares in issue
What is the market cap of Omega Therapeutics?
The market capitalisation of Omega Therapeutics is USD 44,9M
What is the 1 year trading range for Omega Therapeutics share price?
Omega Therapeutics has traded in the range of US$ 0,75 to US$ 6,30 during the past year
What is the PE ratio of Omega Therapeutics?
The price to earnings ratio of Omega Therapeutics is -0,47
What is the cash to sales ratio of Omega Therapeutics?
The cash to sales ratio of Omega Therapeutics is 14,85
What is the reporting currency for Omega Therapeutics?
Omega Therapeutics reports financial results in USD
What is the latest annual turnover for Omega Therapeutics?
The latest annual turnover of Omega Therapeutics is USD 3,09M
What is the latest annual profit for Omega Therapeutics?
The latest annual profit of Omega Therapeutics is USD -97,43M
What is the registered address of Omega Therapeutics?
The registered address for Omega Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Omega Therapeutics website address?
The website address for Omega Therapeutics is www.omegatherapeutics.com
Which industry sector does Omega Therapeutics operate in?
Omega Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
BAOSBaosheng Media Group Holdings Ltd
US$ 7,10
(310,40%)
58,74M
HOURHour Loop Inc
US$ 4,40
(207,69%)
97,42M
GTIGraphjet Technology
US$ 0,61
(168,72%)
265,48M
CREVCarbon Revolution Public Ltd
US$ 9,16
(135,48%)
26,95M
AVGRAvinger Inc
US$ 1,45
(125,72%)
107,53M
SLGLSol Gel Technologies Ltd
US$ 0,9798
(-40,62%)
3,07M
DRCTDirect Digital Holdings Inc
US$ 3,71
(-32,55%)
23,82M
CHEKCheck Cap Ltd
US$ 1,55
(-31,11%)
3,49M
SYTASiyata Mobile Inc
US$ 0,5178
(-30,83%)
2,63M
BTFValkyrie ETF Trust II CoinShares Bitcoin and Ether Stratagy ETF
US$ 15,47
(-30,38%)
147,98k
SVMHSRIVARU Holding Ltd
US$ 0,0338
(20,71%)
280,27M
GTIGraphjet Technology
US$ 0,61
(168,72%)
265,48M
LITMSnow Lake Resources Ltd
US$ 0,5849
(52,84%)
181,22M
LCIDLucid Group Inc
US$ 3,20
(3,23%)
108,75M
RGTIRigetti Computing Inc
US$ 11,35
(3,56%)
108,38M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
OMGA
Omega Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés